Cash flow from investing activities Depreciation and amortization Cash flow from operating activities Employees
At the reporting date
Statement of income Sales revenue
Gross profit EBITDAEBITDA margin as a percentage of sales Operating result (EBIT)
Equity ratio Liquid funds Cash flow
Net result for the period Earnings per share Balance sheet Balance sheet total Equity
2019
2020 *
2021
EUR thousand
19,934
19,668
28,419
EUR thousand
11,783
11,256
12,438
EUR thousand
5,433
4,936
814
%
27.3
25.1
2.9
EUR thousand
2,453
1,973
-3,071
EUR thousand
718
1,439
-3,926
EUR
0.18
0.35
-0.63
Dec. 31, 2019 *
Dec. 31, 2020 *
Dec. 31, 2021
EUR thousand
58,775
58,673
177,946
EUR thousand
28,048
26,231
41,942
%
47.7
44.7
23.6
EUR thousand
9,102
10,396
33,298
2019*
2020
2021
EUR thousand
-1,390
-252
24,871
EUR thousand
2,979
2,964
3,885
EUR thousand
6,318
3,531
2,727
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2021
Number
120
116
775
%27.3
EUR thousand718
EUR thousand-1,390
EUR thousand6,318
*Prior-year figures adjusted. The adjustments are explained in Note 2.3.
Sales revenues in EUR million
1,439-3,926
-25224,871
3,5312,727
EBITDA in EUR million
EBITDA margin as a percentage of sales in %
28 .4
VITA 34 - EUROPE'S LEADING CELL BANK
Vita 34 was founded in Leipzig in 1997 and is today one of the leading cell banks in Europe. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since then been a full-service provider of cryopreservation, offering the collection, processing and storage of stem cells from umbilical cord blood and umbilical cord tissue.
Based on the expansion of the business model in 2019, Vita 34 intends to also offer the storage of immune cells from peripheral blood as well as of stem cells from autologous fat in the future. Additional growth potential exists in new expanding business areas such as cell and gene therapies (including CAR-T) and CDMO.
1
Content
CONTENT
4 To our shareholders
4 Letter from the Management Board
8 Supervisory Board Report
12 Vita 34 AG Shares
16 Combined management report
16 Preliminary note
16 Fundamentals of the Company and the Group
25 Business Report
32 Corporate Governance
32 Opportunity and risk report
37 Forecast report
39 Footnotes
40 Consolidated Financial Statements
42 Consolidated Statement of Income
43 Consolidated Statement of Comprehensive Income
44 Consolidated Balance Sheet
46 Consolidated Statement of Changes in Group Equity
48 Consolidated Cash Flow Statement
50 Notes to the Consolidated Financial Statements for the Fiscal Year 2021
118 Further Information
120 Responsibility Statement
121 Independent Auditor's Report
130 Financial Calendar 2022
131 Imprint
3
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
VITA 34 AG published this content on 30 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 April 2022 22:06:02 UTC.
Vita 34 International AG is a Germany-based company engaged in the medical technology sector. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the childâs birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The Company acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
VITA 34 AG 
